Alpelisib vs Everolimus Sequencing Shows No Clear Winner in PIK3CA Breast Cancer

Hormone receptor-positive, HER2-negative metastatic breast cancer accounts for roughly 70% of all metastatic breast cancer cases, and the PI3K/AKT/mTOR pathway is altered in approximately half of these tumors. After first-line CDK4/6 inhibitor-based therapy, clinicians have several FDA-approved pathway-targeting agents available — everolimus (mTOR inhibitor, approved 2012), alpelisib (PI3K inhibitor, approved 2019), and more recently capivasertib and inavolisib — but the optimal sequencing of these agents has never been rigorously defined. This retrospective single-center study from Memorial Sloan Kettering Cancer Center set out to fill that gap by characterizing outcomes in women who received both everolimus and alpelisib in either order.

The study enrolled 115 women with PIK3CA-mutant HR+/HER2- metastatic breast cancer treated between 2012 and 2023. Sixty-three women (55%) received everolimus first then alpelisib (Group 1), while 52 (45%) received alpelisib first then everolimus (Group 2). Median age was 61 years, 53% had visceral disease, and the cohort was heavily pretreated with a median of 3 prior metastatic lines (IQR 2–4.5). Seventy-one percent had received a prior CDK4/6 inhibitor, though this was significantly more common in Group 2 (87% vs. 59%, p=0.001), reflecting the real-world practice shift toward alpelisib-first after CDK4/6 inhibitor progression.

For the primary endpoint of time to treatment failure on the first pathway agent (TTF1), Group 1 achieved a median of 9.2 months (95%CI 5.5–12.0) and Group 2 achieved 9.7 months (95%CI 7.1–14.0), a non-significant difference (p=0.5). In the subgroup with prior CDK4/6 inhibitor use, TTF1 was markedly shorter in Group 1 at 4.3 months versus 8.7 months in Group 2 (p=0.02), but this difference disappeared after multivariable adjustment, confirming that CDK4/6 inhibitor history rather than drug sequence drove the disparity. Overall median TTF on the second pathway agent (TTF2) was just 4.1 months (95%CI 3.5–5.1), highlighting how quickly resistance emerges after both agents have been used.

Multivariable Cox proportional hazards analysis identified prior CDK4/6 inhibitor use (HR 3.6, 95%CI 2.0–6.3, p<0.001) and greater number of prior treatment lines (HR 1.1, 95%CI 1.0–1.3, p=0.01) as the dominant negative predictors of TTF1, while treatment group assignment was non-significant (p=0.2). Notably, a GATA3 mutation was significantly associated with worse alpelisib-specific TTF (p=0.016), pointing to a potential biomarker for patient selection. Use of an aromatase inhibitor versus fulvestrant as the endocrine partner was associated with better TTF1 in the CDK4/6 inhibitor-exposed subgroup (HR 0.47, p=0.02).

The study has important clinical implications as the treatment landscape evolves. The arrival of capivasertib and inavolisib means oncologists now face even more complex sequencing decisions across an expanding set of PI3K/AKT/mTOR-targeted agents. This real-world dataset, while limited by retrospective design and absence of a control arm, establishes that re-challenging with a second pathway agent yields a median TTF2 of only about four months, and that the cumulative burden of prior CDK4/6 inhibitor therapy is the strongest modifiable predictor of failure. Prospective trials with embedded biomarker analyses — particularly assessing co-mutations like GATA3 — are urgently needed to guide sequencing in this increasingly complex setting.